CFRX ContraFect Corporation

2.00
0  -2%
Previous Close 2.05
Open 2.00
Price To book 4.38
Market Cap 83.31M
Shares 41,656,000
Volume 2,257
Short Ratio 2.82
Av. Daily Volume 49,202

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced January 6, 2017 that its Phase 2 trial initiation has been delayed until mid-2017.
CF-301
Serious infections caused byStaph aureus including MRSA

Latest News

  1. CONTRAFECT CORP Financials
  2. CFRX: Phase 2 Trial of CF-301 to Initiate in mid-2017
  3. CONTRAFECT CORP Files SEC form 10-K, Annual Report
  4. CORRECTION - ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  5. ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  6. CONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
  7. ContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave
  8. CONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers
  9. Lisa Ricciardi to Join Board of Directors
  10. ContraFect Provides Program Update
  11. ContraFect Provides Program Update
  12. ContraFect to Present at Biotech Showcase 2017 Conference
  13. Is ContraFect Corp (CFRX) A Good Stock To Buy?
  14. ContraFect Corp. :CFRX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  15. The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3
  16. ContraFect to Present at 28th Annual Piper Jaffray Healthcare Conference
  17. ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301
  18. CFRX: Preparations Continue for Launch of Phase 2 Clinical Trial of CF-301 in 4Q16…
  19. ContraFect Announces Expanded Research Collaboration with The Rockefeller University to Identify Lysin Therapeutics Targeting Gram-negative Bacteria
  20. ContraFect to Present at The Lysin Meeting